Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Carcinoma, Transitional Cell
  • Deoxycytidine
  • Urinary Bladder Neoplasms

abstract

  • Gemcitabine has substantial activity as an intravesical agent in BCG-refractory TCC and warrants further investigation. Therapy given twice weekly was associated with minimal bladder irritation and tolerable myelosuppression. The recommended phase II dose for twice-weekly therapy is 2,000 mg.

publication date

  • August 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2002.02.066

PubMed ID

  • 12149290

Additional Document Info

start page

  • 3193

end page

  • 8

volume

  • 20

number

  • 15